For the past couple of years, interest in cannabidol (CBD) has been gaining traction in Europe and the U.S., mostly caused by the cannabis extract’s abilities as a versatile natural medication. Although there has been little conclusive scientific research on the efficacy and side effects of CBD, there is plenty of anecdotal evidence claiming it is effective against a host of medical conditions ranging from anxiety to chronic pain and high blood pressure. Now it seems that cannabidiol has another use up its sleeve.
The subject of cannabinoids and dementia, and whether CBD can be used to alleviate common age-related medical conditions was tabled at a debate in Rio de Janeiro, promoted by the Brazilian Society of Geriatrics and Gerontology (SBGG). International case studies on cannabinoids and dementia were presented by Ivan Abdalla, a physician at the Alzheimer’s Dementia Center of Psychiatry Institute of the Federal University of Rio de Janeiro (IPUB-UFRJ).
He presented a map made by the Canadian Agency on Drugs and Health Technologies (CADTH) after surveying 12 studies conducted between 1997 and 2017 in Canada, the United States, the United Kingdom, Israel, Netherlands, Germany and Switzerland. According to him, the studies point out the need to deepen our understanding of the effects on real life patients before cannabis is prescribed as a treatment in the field or geriatrics.
He added that although we may already have evidence that shows that it does have a positive effect, we have to walk a few more steps to be more certain. “They have evidence for some clinical situations,” he says, “but we still don’t have that conclusive answer. There is potential, but we are still in an experimental moment. It is necessary to stimulate research and debate and break down barriers to this, rather than use it.”
Claudia Burla, one of the founders of the Palliative Care Commission of SBGG mediated the debate. She says that she has no doubt that cannabinoids can have a great therapeutic potential for the elderly. “We have to study, we cannot remain in reductionism and amoralism,” she says, adding that caution must be exercised in the debate to prevent unrealistic expectations.
According to Carlos Andre Uehara, any CBD medical prescriptions for the elderly still requires more studies, but that the role of a scientific society is to support the debate. “It does not prevent us from having the discussion.”
Analysts believe such expert debates are a welcome activity for sector players like HTC Extraction Systems (TSX.V: HTC) and VPR Brands LP (OTCQB: VPRB) who have always wanted the scientific community to be involved in driving the debate around this cannabinoid with immense therapeutic potential.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
